Assistive Reproductive Technology Market to Surpass US$ 37.6 Bn by 2027

Global Assistive Reproductive Technology Market, by Product Type (Consumables  and Instruments), by Technology (In-vitro fertilization (IVF) (IVF with Intracytoplasmic Sperm Injection (ICSI) and IVF without Intracytoplasmic Sperm Injection (ICSI), Artificial Insemination-Intrauterine Insemination (AI-IUI), Frozen Embryo Replacement (FER) and Others); by Procedure (Fresh Donor, Frozen Donor, Fresh Nondonor, Frozen Nondonor, Embryo/Egg Banking, and Others; by End User (Fertility Clinics, IVF Center, and Hospital), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) was valued at US$ 23.6 Bn in 2018 and is projected to exhibit a CAGR of 5.3% over the forecast period (2019–2027), as highlighted in a new report published by .

Frequent product launches, approvals are expected to drive the global assistive reproductive technology market growth in the forecast period Manufacturers are focused on launching products and expanding their offerings of ART. In August 2017, Hamilton Thorne Ltd., provider of precision instruments, consumables, software and services, launched TrakJector, a micromanipulator system which offers unique and intuitive control over fast and accurate Intracytoplasmic sperm injection (ICSI) and embryo biopsy procedures in ART laboratories. In October 2017, Hamilton Thorne Ltd., a world-wide provider of assisted reproductive technologies (ART), announced the expansion of range of products for its ART market, on a direct sales basis in North America. The range of products includes,

Gynemed Glass Micropipettes, Micromanipulation System, Hamilton Thorne DuraSlides, Halosperm DNA Fragmentation Kits and others. In July 2018, Merck KGaA, a science and technology company, announced the launch of QBOX IVF, it streamlines data transfer between lab instruments and electronic medical record (EMR) providers. In the same year and month they also launched the new Geri Assess 2.0 which enables automatic detection of key events in embryo and blastocyst development, improves efficiency in embryo assessment, these two products are used in IVF and ART clinics. Moreover, in October 2016, EMD Serono, the biopharmaceutical business of Merck KGaA, announced the launch of New Fertility Technologies Division, at the 72^nd American Society for Reproductive Medicine (ASRM) Scientific Congress. 

Increasing prevalence and incidence of infertility is expected to drive the global assistive reproductive technology market growth in near future Increase in prevalence and incidence of infertility rates has led to increase in the number of ART clinics. For instance, according to National Centers for Chronic Disease Prevention and Health Promotion, there are total 499 ART clinics in the U.S., among which 464 clinics had reported the data (related to ART procedures) to CDC, which states that overall, 231,936 number of ART cycles were performed by 464 clinics in U.S in 2015.

Browse 37 Market Data Tables, and 25 Figures spread through 170 Pages and in-depth TOC on Global Assistive Reproductive Technology Market, by Product Type (Consumables  and Instruments); by Technology (In-vitro fertilization (IVF) (IVF with Intracytoplasmic Sperm Injection (ICSI) and IVF without Intracytoplasmic Sperm Injection (ICSI), Artificial Insemination-Intrauterine Insemination (AI-IUI), Frozen Embryo Replacement (FER) and Others; by Procedure (Fresh Donor, Frozen Donor, Fresh Nondonor, Frozen Nondonor, Embryo/Egg Banking and Others; by End User (Fertility Clinics, IVF Center and Hospital); and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027

To know the latest trends and insights prevalent in the Global Assistive Reproductive Technology Market, click the link below: https://www.coherentmarketinsights.com/market-insight/assistive-reproductive-technology-market-3041

Key players in the market are involved in strategic acquisitions in order to expand their product portfolio. For instance, in April 2018, Cooper Surgical Inc. acquired LifeGlobal Group and its affiliates, a global provider of in-vitro fertilization (IVF) devices. This acquisition is expected to strengthen Cooper Surgical’s fertility media offerings and help improve their fertility business. In February 2016, Cooper Surgical Inc., acquired The Pipette Company (TPC), a manufacturer and distributor of micropipettes in the ART market, based in Adelaide, Australia.

Key Takeaways of the Global Assistive Reproductive Technology Market:

• The global assistive reproductive technology market is expected to exhibit a CAGR of 5.3% over the forecast period (2019–2027) owing to frequent launches and approvals of assistive reproductive technology products
• Among region, North America is expected to hold a dominant position in the global assistive reproductive technology market owing to increase in ART centers and rising awareness about ART among the populace
• Asia Pacific and Europe is expected to be a potential markets owing to increasing infertility rates among people aged 35-40, and increasing awareness of IVF procedures and ART technologies
• Major players operating in the global assistive reproductive technology market include Cooper Surgical Inc., Hamilton Thorne, Inc., FUJIFILM Irvine Scientific, Inc., Merck KGaA, Nidacon International AB, Vitrolife AB, EMD Serono, Inc., INVO Bioscience, IVFtech ApS, Gonagen Medikal, Cook Medical LLC, and CellCura ASA